Our team uses a validated approach to develop novel siRNA-based therapeutics for significant markets with high unmet clinical need. Using a proprietary platform for siRNA sequence prediction against targets to rapidly identify siRNA candidates.
PC is leveraging an unsurpassed level of knowledge and experience in RNA interference technology and forging a path to high value creation in genetic diseases and cancer therapeutic areas with significant unmet medical need.
Gene therapy is one of the most revolutionary medical technology. It is a biomedical treatment based on changing human genetic material, which shows a unique advantage in the treatment of major diseases.
The Potential to Treat Multiple Malignancies
KR-IF-0715 is a therapy composed of siRNA targeting KRAS formulated in stable nucleic acid-lipid particles.
The Gene Silencing Strategy to “Switch off” PD-L1 Translation
PD-IF-032 is a siRNA loaded into exosome to suppress PD-L1 expression with high target-specificity.
Pharma company (PC) is a biopharmaceutical company leveraging an outstanding level of knowledge and experience in RNA interference (RNAi) technology to forge a path to high value creation through discovery and development of therapeutics for human disorders with unmet medical needs.
We are mastering a key and unique technique for small interfering RNA drug delivery. Through the internal research and collaborations with prominent labs, we have developed a strong portfolio of intellectual property covering RNAi therapeutic products.
Pushing the boundaries for life science research
Pharma company is on a mission to advance our proprietary platform for gene therapy and to transform the lives of patients through effective therapies.
Copyright © Acevirt. All rights reserved.